Dianna Sue Howard, M.D.
Professor, Hematology & Oncology
Academic: 336-716-4464 | Department: 336-716-4464
Saeed H, Slone S, Yalamanchi S, Becton T, Monohan G, Howard D, Herzig R, Hildebrandt GC. Acute graft-versus-host disease in the setting of T cell depletion: validation of a new agvhd risk score [abstract]. Biol Blood Marrow Transplant. 2016;22(3 Suppl 1):S410-S411.
Lamar ZS, Fino N, Hurd D, Howard D, McIver ZA, Phillips GL, Vaidya R. Timing of salvage therapy and autologous hematopoietic cell transplant in relapsed hodgkin and non hodgkin lymphoma [abstract]. Biol Blood Marrow Transplant. 2016;22(3 Suppl 1):S127-S128.
Carroll D, Howard D, Zhu H, Paumi CM, Vore M, Bondada S, Liang Y, Wang C, St Clair DK. Simultaneous quantitation of oxidized and reduced glutathione via LC-MS/MS: an insight into the redox state of hematopoietic stem cells. Free Radic Biol Med. 2016;97():85-94.
Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. J Clin Oncol. 2015;33(15 Suppl):7015.
Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL. The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Blood. 2015;126(23):2556.
Klepin HD, Tooze J, Pardee T, Ellis LR, Berenzon D, Howard D, Demark-Wahnefried W, Mihalko S, Rejeski WJ, Powell BL, Kritchevsky S. Feasibility of a symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) [abstract]. Blood. 2015;126(23):2102.
Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014;61(10):1754-1760.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
Professor, Hematology & Oncology
Acute and Chronic Leukemia, Acute Leukemias, Myelodysplastic Syndromes, Blood and Marrow Transplant, Hematologic Malignancies, Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Bone Marrow and Stem Cell Transplantation, Leukemia
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
I was very happy with my first visit with *Dr. Howard.
Dr. Howard a Great Person